Glenmark greenlighted to market hypertension generic in US

pharmafile | May 30, 2017 | News story | Manufacturing and Production, Sales and Marketing FDA, Glenmark, generic, hypertension 

Glenmark Pharmaceuticals has revealed it has been awarded final approval by the FDA to market hypertension treatment nebivolol, a generic version of Forest Laboratories’ Bystolic.

Glenmark reached a previous agreement with Forest which enables it to commercialise and distribute the drug three months before its US patent expiration, including any extensions and/or paediatric exclusivity. In addition, the firm may find itself eligible for 180 days generic exclusivity for nebivolol.

“With respect to 180-day generic drug exclusivity, the FDA noted that Glenmark was one of the first Abbreviated New Drug Application (ANDA) applicants to submit a substantially complete ANDA with a paragraph IV certification for nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg,” noted Glenmark’s BSE filing.

Hypertension, also known as high blood pressure, can potentially present the risk of stroke or heart attack. Blood pressure is traditionally lowered through the use of beta blockers – a drug group of which nebivolol is a member. The approval is good news for Glenmark, who will be looking to capitalise on the $1 billion annual sales achieved by its originator product Bystolic last year; however, research released this week could cast a shadow as it is found that beta blockers have little to no effect on 95% of heart attack sufferers who have not also experienced heart failure.

Matt Fellows

Related Content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) …

FDA approves Roche’s HPV self-collection screening option

Roche has announced that the US Food and Drug Administration (FDA) has approved its human …

Moderna shares update on RSV vaccine

Moderna has announced that the US Food and Drug Administration (FDA) has shared that it …

Latest content